|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions</b>: CRT is comparable to IMRT alone for elderly patients with locoregionally advanced NPC.
|
31737097 |
2019 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA.
|
31200353 |
2019 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion</b>: CALR may promote NPC progression and metastasis via involving Stat3 signaling pathway, and can be regarded as an effective potential predictor for progression and prognosis of NPC.
|
31632490 |
2019 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pre-C-CRT hemoglobin <11.0 g/dL has a stronger prognostic worth than the anemia status with regard to LRPFS, progression-free survival, and overall survival for nasopharyngeal carcinoma patients.
|
30864463 |
2019 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Eligible patients with stage III-IVB nonkeratinizing NPC were randomly assigned to radiation therapy alone (RT: 218 patients) or chemoradiation therapy (CRT: 223 patients) using 3 cycles of cisplatin (100 mg/m<sup>2</sup>) concurrent with RT, followed by 3 cycles of cisplatin (80 mg/m<sup>2</sup>) and fluorouracil (1000 mg/m<sup>2</sup>/day for 4 days).
|
29885997 |
2018 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
From May 2001 to April 2015; 62 newly diagnosed NPC patients were treated with three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) with or without CCT.
|
29718841 |
2018 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altered fractionated and conventional fractionated RT achieved similar survival outcome when concurrent CRT strategy was used for advanced NPC.
|
29389048 |
2018 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, 3D-CRT with a dose of 62/1.8-2 Gy is a safe, effective and tolerable treatment for NPC patients with good clinical value.
|
28943965 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study concludes that the IMRT and the 3D-CRT have almost the same short-term and long-term clinical effects in the treatment of nasopharyngeal carcinoma and both of them have high effectiveness and safety.
|
29344223 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, IMRT improves the QoL of patients with stage II NPC as compared to 2D-CRT.
|
28515352 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In our previous study, five different secretory proteins, including GSN, ADAMTSL4, CALR, PPIA and TXN, have been identified to be associated with the nasopharyngeal carcinoma (NPC) metastasis.In this work, the 5 proteins were further investigated.
|
28107202 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To compare the clinical outcomes and toxicities of two-dimensional conventional radiotherapy (2D-CRT) and intensity-modulated radiotherapy (IMRT) for the treatment of children and adolescent nasopharyngeal carcinoma (NPC).
|
28342002 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
From November 2007 to December 2011, 255 patients with histologically diagnosed, non-metastatic NPC were enrolled into this study and received 4F-CRT.
|
28055973 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Stage II (2010 UICC/AJCC staging system) NPC patients treated with IMRT (n = 178) or 2D-CRT (n = 73) between January 2007 and December 2014 were retrospectively analyzed.
|
29100451 |
2017 |